FY2024 Earnings Forecast for Moderna, Inc. Issued By Zacks Research (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) – Equities research analysts at Zacks Research cut their FY2024 earnings per share estimates for shares of Moderna in a report released on Wednesday, September 11th. Zacks Research analyst S. Ganoria now anticipates that the company will earn ($9.53) per share for the year, down from their prior forecast of ($9.38). The consensus estimate for Moderna’s current full-year earnings is ($9.52) per share. Zacks Research also issued estimates for Moderna’s Q4 2024 earnings at ($1.30) EPS, Q2 2025 earnings at ($3.39) EPS, Q3 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($8.74) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.10) EPS and FY2026 earnings at ($6.06) EPS.

A number of other brokerages have also commented on MRNA. JPMorgan Chase & Co. lowered their price objective on Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research report on Wednesday, August 28th. The Goldman Sachs Group decreased their price objective on shares of Moderna from $204.00 to $178.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and dropped their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Finally, Oppenheimer upped their price target on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Ten analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Moderna has an average rating of “Hold” and an average price target of $123.79.

Moderna Stock Down 12.4 %

Shares of Moderna stock opened at $69.68 on Friday. Moderna has a 1 year low of $62.55 and a 1 year high of $170.47. The company has a market cap of $26.70 billion, a P/E ratio of -4.45 and a beta of 1.67. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average price of $96.06 and a 200 day moving average price of $111.86.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter in the previous year, the company earned ($3.62) earnings per share. The firm’s quarterly revenue was down 29.9% compared to the same quarter last year.

Insider Buying and Selling

In other news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total value of $1,799,400.00. Following the completion of the transaction, the director now owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. The disclosure for this sale can be found here. In the last three months, insiders sold 108,158 shares of company stock valued at $13,239,712. 15.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Principal Securities Inc. bought a new position in shares of Moderna during the fourth quarter worth approximately $198,000. NBC Securities Inc. lifted its holdings in shares of Moderna by 20.2% during the fourth quarter. NBC Securities Inc. now owns 1,222 shares of the company’s stock worth $121,000 after buying an additional 205 shares in the last quarter. Jump Financial LLC boosted its position in shares of Moderna by 402.2% in the fourth quarter. Jump Financial LLC now owns 13,835 shares of the company’s stock valued at $1,376,000 after acquiring an additional 11,080 shares during the period. Ieq Capital LLC increased its position in Moderna by 62.0% during the fourth quarter. Ieq Capital LLC now owns 8,693 shares of the company’s stock worth $865,000 after acquiring an additional 3,326 shares during the period. Finally, Westpac Banking Corp raised its stake in Moderna by 14.3% in the 4th quarter. Westpac Banking Corp now owns 3,805 shares of the company’s stock worth $378,000 after purchasing an additional 476 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.